Pharma Focus Europe

Willow and Suanfarma Collaborate to Enhance Development of High-volume Anti-infective API

Wednesday, October 04, 2023

Willow Biosciences Inc. (TSX: WLLW) (OTCQB: CANSF) and SUANFARMA have jointly revealed a collaboration agreement to enhance cell line productivity for the production of a high-volume anti-infective active pharmaceutical ingredient (API) through precision fermentation. In this partnership, SUANFARMA will utilize Willow's patented strain optimization technologies to streamline the production process for the API, making it more cost-effective.

By leveraging Willow's strain engineering technology platform, SUANFARMA aims to improve the commercial production of the API at its manufacturing facility, reducing costs and maximizing product quality.

Chris Savile, President and CEO of Willow, expressed enthusiasm about expanding their successful partnership with SUANFARMA to deliver sustainably sourced products that benefit human health and well-being through innovative production methods.

Daniel Rivero, Industrial Director of SUANFARMA CDMO, also shared his excitement about extending their collaboration with Willow to develop commercial products, emphasizing their commitment to enhancing product quality while reducing production costs through fermentation technology. They plan to scale up production in Europe once successful development is achieved.

SUANFARMA CDMO specializes in contract development and manufacturing services, with expertise in fermentation, purification, and chemical synthesis technologies for the pharmaceutical and biotechnology industry. They offer a comprehensive approach to technology transfer through their TT&GO® platform, ensuring efficient industrialization and rapid commercialization of final products.

This collaboration builds upon a previous alliance announced in March 2023, where Willow and SUANFARMA intended to work together on synthetic molecules, including anti-infectives and other pharmaceutical intermediates, catering to the health and wellness as well as food and beverage industries. Today's announcement signifies another milestone in expanding their partnership by providing a comprehensive synthetic biology solution and diversifying their joint product portfolio.

magazine-slider-img
Thermo Fisher Scientific - mRNA ServicesWorld Orphan Drug Congress 2024World Vaccine Congress Europe 2024Advanced Therapies USA 2024
cytiva